Fusion Research
Research analyst, oil & gas, tech, mid-cap

Questcor: Near The Tipping Point

Questcor (QCOR) is a biotechnology company focused on providing prescription drugs for central nervous system disorders. It offers ''Acthar'', the sole revenue driving drug, which treats patients with multiple sclerosis and infantile spasms. Acthar, in the first quarter of 2013, reported $126 million in revenue, compared to the company's total revenue of $135.1 million. This drug accounts to 93% of the total revenue. Its key areas of focus are neurology, nephrology, and rheumatology. The company makes research initiatives on a variety of medical conditions that are not completely controlled or cured with existing drugs on the market.

Acthar will bring additional upside on the revenue

Questcor's Acthar has received FDA approval for 19 separate indications in the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details